Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) today announced that Ken Cohen, president and chief executive officer, will present at the following two upcoming investor conferences:
Merriman Curhan Ford 4th Annual Investor Summit
Monday, September 17, 2007, at 8:00 a.m. PT (11:00 a.m. ET)
Mark Hopkins InterContinental Hotel - San Francisco, CA
ThinkEquity Partners G5: The Growth Conference
Tuesday, September 18, 2007, at 9:30 a.m. PT (12:30 p.m. ET)
St. Regis Hotel - San Francisco, CA
A live webcast of each of the presentations will be available in the Investor Relations section of the company’s website under Event Scheduler at www.somaxon.com. The webcasts will be archived and accessible for at least 14 days.
About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia. The company has completed a pilot Phase 2 trial for nalmefene in smoking cessation with positive results. It has also completed a Phase 2/3 clinical trial for nalmefene for the treatment of pathological gambling that did not achieve statistical significance for the primary or secondary endpoints. The company will evaluate the results from both of these trials before making determinations regarding the future of the nalmefene program. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.
For more information, please visit the company’s web site at www.somaxon.com.